Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
Juan Sanchez - Vice President, Corporate Communications and Investor Relations
Sharon Mates - Chairman and Chief Executive Officer
Mark Neumann - Executive Vice President and Chief Commercial Officer
Suresh Durgam - Executive Vice President Chief Medical Officer
Larry Hineline - Senior Vice President and Chief Financial Officer
Conference Call Participants
Andrew Tsai - Jefferies
Jessica Fye - JPMorgan
Mike DiFiore - Evercore
Brian Abrahams - RBC Capital Markets
Charles Duncan - Cantor Fitzgerald
Marc Goodman - SVB
Karin Jenkins - Goldman Sachs
Jason Gerberry - Bank of America
Ash Verma - UBS
Sumant Kulkarni - Canaccord
Operator
Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies' Second Quarter Earnings Call. At this time, all participants on a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, today's conference is being recorded.
I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Thank you. Please go ahead.
Juan Sanchez
Good morning, and thank you all for joining us on the call today. Our earnings press release provides a corporate update and details of the company's financial results for the second quarter ended June 30, 2022. The press release crossed the wire earlier this morning and is available on our website at intracellulartherapies.com.
Joining me on the all today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; Dr. Suresh Durgam, Executive Vice President and Chief Commercial Medical Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer.
As a reminder, during today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended use of the company's product development candidates, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and results of ongoing and future clinical trials, plans regarding regulatory filings, future research and development, our plans and expectations regarding the commercialization of CAPLYTA; the potential impact of the COVID-19 pandemic on our business; and possible uses of existing cash and investment resources.
These forward-looking statements are based on current information, assumptions and expectations. Those are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our previous filings made with the Securities and Exchange Commission including our quarterly and annual reports. You're cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligations to update such statements.